Multidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma
Kevin C. Flanagan, Eric J. Duncavage(Washington University in St. Louis), Jessica Ley(Washington University in St. Louis), Karim Welaya(CoxHealth), Bruce Bank, Ida Deichaite(Moores Cancer Center), Xingwei Sui(Providence Regional Cancer Partnership), Howard L. McLeod(Unknown), Scott A. Sonnier(Touro Infirmary Foundation), Vera Vavinskaya(University of California San Diego), Jarret Glasscock(Cofactor Genomics (United States)), Steven J. Saccaro, Natalie A. LaFranzo(Cofactor Genomics (United States)), Vlad C. Sandulache(Michael E. DeBakey VA Medical Center), William H. Westra(Mount Sinai Hospital), Jon Earls(Cofactor Genomics (United States)), Raymond Y. Hsu, Warren L. Alexander(William Beaumont Army Medical Center), Charles Bane(Dayton Physicians Network), Ian Schillebeeckx(Cofactor Genomics (United States)), D. Messina(Cofactor Genomics (United States)), Matthew Rendo(Brooke Army Medical Center), O. Kenneth Macdonald(Cancer Care Northwest), Todd D. Shenkenberg(Valley Baptist Medical Center), Lincoln Nadauld(Intermountain Healthcare), Savitha Balaraman, Katherine A. Price(Mayo Clinic), James L. Wade(American Society of Clinical Oncology), Jennifer N. Slim(MultiCare Health System), Douglas R. Adkins(Washington University in St. Louis), Josh Fuller(Intermountain Healthcare), Leisa Sutton(Moores Cancer Center), Sean D. Firth(Intermountain Healthcare), Rachel L. Wellinghoff(Cofactor Genomics (United States)), Samuel D. Bailey(Appalachian Regional Healthcare), Zachary S. Bradley(Cofactor Genomics (United States)), Jeffrey Hiken(Cofactor Genomics (United States)), Andrew W. Pippas, Adil Akhtar, Brittany Sharp(Intermountain Healthcare), Ezra E.W. Cohen(Moores Cancer Center), J T Babbitt(Cofactor Genomics (United States)), Steven E. Kossman
Cited by 8
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours
|Nature Genetics|1995|646